Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK
- This topic has 0 replies, 1 voice, and was last updated 1 year, 11 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), and biliary tract cancer (BTC). There is no formal hypothesis testing in this study.
https://www.clinicaltrials.gov/ct2/show/NCT04976634
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.